

Anti-CD21 [RM372]

Catalog No.	Description
ANA18-5M	6 ml of Ready-to-Use Antibody for Use with BioGenex Super Sensitive Detection Systems or Other Equivalent Detection Systems
ANA18-10M	10 ml of Ready-to-Use Antibody in a barcode labeled vial for Use with BioGenex Super Sensitive Detection Systems and BioGenex i6000 Automated Staining Systems
NUA18-UC	1 ml of Concentrated Antibody for Use with BioGenex Super Sensitive Detection Systems or Other Equivalent Detection Systems
NUA18-5UC	0.5 ml of Concentrated Antibody for Use with BioGenex Super Sensitive Detection Systems or Other Equivalent Detection Systems
AYA18-YCD	Ready-to-Use Antibody in barcoded vial for use on the Xmatrix [®] Elite/Ultra Staining System, 200 tests
AYA18-50D	Ready-to-Use Antibody in barcoded vial for use on the Xmatrix [®] Elite/Ultra Staining System, 50 tests

Immunogen	Clone	Species	Ig Class
A peptide corresponding to the C-terminus of human CD21 (Complement receptor type 2).	RM372	Rabbit	IgG

Intended Use

For In-Vitro Diagnostic Use.

This antibody is currently available for in vitro diagnostic use. This antibody is designed for the specific localization of CD21 in formalin fixed, Paraffin-embedded tissue sections.

Summary and Explanation

CD21 is a single-pass type 2 transmembrane protein that serves as the complement receptor for C3d and the Epstein-Barr virus. Anti-CD21 is valuable in differentiating follicular lymphoma with marginal zone differentiation from marginal zone lymphoma with follicular involvement. It also plays a role in separating among nodular lymphocyte predominant Hodgkin lymphoma, lymphocyte-rich classic Hodgkin lymphoma, and T-cell/histiocyte-rich B-cell lymphoma in combination with other B-cell and T-cell markers. The antigen is absent on T-Lymphocytes, monocytes, and granulocytes.

Principles of the Procedure

The demonstration of antigens by immunohistochemistry (IHC) is a twostep process involving first, the binding of a primary antibody to the antigen of interest, and second, the detection of bound antibody by a chromogen. The primary antibody may be used in IHC using manual techniques or using BioGenex Automated Staining System. BioGenex offers a variety of Super Sensitive detection systems including Link-Label and Polymer-based technologies to detect the chromogenic signal from the stained tissues and cells.

Positive and negative controls should be run simultaneously with all patient specimens. If unexpected staining is observed which cannot be explained by variations in laboratory procedures and a problem with the antibody is suspected, contact BioGenex Technical Support at 1.800.421.4149 or your local distributor.

Reagents Provided

Rabbit Monoclonal Antibody to CD21 is affinity purified and diluted in PBS, pH 7.2, containing 1% BSA and 0.09% sodium azide.

Dilution of Primary Antibody

BioGenex Ready-to-Use antibodies have been optimized for use with the recommended BioGenex Detection System and should not require further dilution. Further dilution may result in loss of sensitivity and must be validated by the user.

BioGenex concentrated antibodies must be diluted in accordance with the staining procedure when used with the recommended BioGenex Detection System (see staining procedure section below). Use of any detection methods other than the recommended systems and protocols, require validation by the user.

Materials Required But Not Provided

All the materials and reagents necessary for IHC are not provided. Pre-treatment reagents, Super Sensitive Detection Systems, control reagents and control slides; other ancillary reagents are available from BioGenex. Please refer to the product insert(s) of the BioGenex Super Sensitive IHC detection systems for detailed protocols and instructions.

The IHC procedure may need other lab equipment that is not provided including oven or incubator (capable of maintaining 56-60°C), BioGenex [Automated Staining System](#), Humidity Chamber, Microwave oven, Staining Jars or baths, Timer (capable of 3-20 minute intervals), Wash Bottles, Absorbent Wipes, Microscope slides (Aptec coated), Coverslips, Lens paper and Light microscope with magnification of 200X.

Storage and Handling

Antibodies should be stored at 2-8°C without any further dilution. Fresh dilutions, if required, should be prepared prior to use and are stable and steady for up to one day at room temperature (20-26°C). The antibody should not dry out during its intended incubation period when used as directed. Unused vial of antibody preparations should be discarded after one day to minimize microbial contamination and non-specific staining. Diluted antibody preparations can be refrigerated or frozen for extended shelf life.

This antibody is suitable for use until expiry date when stored at 2-8°C. Do not use product after the expiration date printed on vial. If reagents are stored under a condition other than those specified in the package insert, they must be verified by the user (6).

The presence of precipitate or an unusual odor indicates that the antibody is deteriorating and should not be used.

Specimen Collection and Preparation

Tissues fixed in 10% (v/v) formalin, prior to paraffin embedding, are suitable for use. For further details on specimen preparation please refer *Histological and Histochemical Methods: Theory and Practice* (7).

The user is advised to validate the use of the products with their tissue specimens prepared and handled in accordance with their laboratory practices.

Treatment of Tissues Prior to Staining

Pretreatment of tissues, if any, should be done as suggested in the staining procedure section below

Precautions

This antibody contains no hazardous material at a reportable concentration according to U.S. 29 CFR 1910.1200, OSHA Hazard Communication Standard and EC Directive 91/155/EC. However, this product contains sodium azide, at concentrations of less than 0.1%. Sodium azide is not classified as a hazardous chemical at the product concentrations. However, toxicity information regarding sodium azide at product concentrations has not been thoroughly investigated. Sodium azide may react with lead or copper plumbing to form highly explosive metal azides. Upon disposal, flush with large volumes of water to prevent azide build-up in plumbing (8). For more information, a Safety Data Sheet (SDS) for

Category	Antibodies	Revision No.	C
Document No.	932-A18N-EN	Release Date	September 25, 2020



sodium azide in pure form is available upon request. Dispose unused reagents according to Local, State and Federal Regulations. Wear suitable Personal Protective Equipment, do not pipette reagents by mouth, and avoid contact of reagents and specimens with skin and mucous membranes. If reagents or specimens come in contact with sensitive area, wash with copious amounts of water (9).

Refer to appropriate product inserts for instructions of use and safety information on detection reagents and other materials, which may be used with the antibody.

Recommended Protocol

Refer to the following table for conditions specifically recommended for this antibody. Refer to the detection system package insert for guidance on specific staining protocols or other requirements.

Parameter	BioGenex Recommendations
Control Tissue	TONSIL as available with Biogenex FB-A18N* & FG-A18N*
Recommended Dilution for Concentrated Ab	1:50-100 in HK941
Recommended Pretreatment (manual/i6000)**	EZ-AR2 (HK522-XAK)
Recommended Pretreatment(Xmatrix)	EZ-AR2 Elegance (HX032-YCD)
Antibody incubation(manual/i6000)	30 min at RT
Antibody incubation (Xmatrix)	45 mins at 25°C
Detection System for manual, Xmatrix & i6000 -Open systems**	Use two-Step Super Sensitive™ Polymer-HRP IHC Detection System/DAB available from BioGenex (QD400 for Manual and QD410, QD550 for Automation).

*FB: positive control barrier slides, FG: positive control non barrier slides. Xmatrix requires barrier slides.

** Pretreatment times will vary based on individual microwave power

***For Closed system automation (Xmatrix-Elite, Xmatrix-Ultra & i6000 diagnostics)

– Please refer to the factory protocols provided with the instrument

Quality Control

The suggested positive control tissue for this particular antibody is Tonsil tissue. The user is always advised to use the control tissues available from BioGenex for your Quality Control purpose. Refer to the appropriate detection system package inserts for guidance on general quality control procedures.

Troubleshooting

Refer to the troubleshooting section in the package inserts of BioGenex Detection Systems (or other equivalent detection systems) for remedial actions on detection system related issues, or contact BioGenex Technical Support Department at 1-800-421-4149 or your local distributor to report unusual staining.

Expected Results

This antibody stains cell membrane in positive cells in formalin-fixed, paraffin embedded tissue sections. Interpretation of the staining result is solely the responsibility of the user. Any experimental result should be confirmed by a medically established diagnostic product or procedure

Limitations of the Procedure

Immunohistochemistry is a complex procedure relating both histological and immunological detection. Improper tissue handling and processing prior to immunostaining can lead to inconsistent results. Variations in embedding and fixation or the nature of the tissue may lead to variations in results. Endogenous peroxidase activity or pseudoperoxidase activity in erythrocytes and tissue biotin









may result in non-specific staining based on the detection system employed. Tissues containing Hepatitis B Surface Antigen (HBsAg) may give false positive with horseradish peroxidase systems (10). Improper counterstaining and mounting may compromise the interpretation of results.

Performance Characteristics

BioGenex has conducted studies to evaluate and determine the performance of the antibody with BioGenex detection systems and accessories. The antibodies have been found to be very specific and sensitive and they show specific binding to the antigen of interest with minimal to no binding to non-specific tissues or cells. BioGenex antibodies have shown reproducible and consistent results when used within a single run, between runs, between lots and wherever applicable between manual and automated runs. The products have been determined to be stable for the periods specified on the labels either by standard real time or accelerated methods. BioGenex ensures product quality through 100% quality control for all products released and through surveillance programs.

Bibliography

- Barel M, et al: Mol. Immunol. 35: 1025-1031.
- Bagdi E, et al: "Follicular dendritic cells in reactive and neoplastic lymphoid tissues: a re-evaluation of staining patterns of CD21, CD23, and CD35 antibodies in paraffin sections after wet heat-induced epitope retrieval. Appl Immunohistochem Molecul Morphol" 2001;9:117-24.
- Weis JJ, et al.: J Exp Med 1988, 167:1047-1066
- Levy E, Ambrus J, Kahl L, et al. (1992). "T lymphocyte expression of complement receptor 2 (CR2/CD21): a role in adhesive cell-cell interactions and dysregulation in a patient with systemic lupus erythematosus (SLE)". Clin. Exp. Immunol. 90 (2): 235–44 Prot A.E. et al: Proc. Natl. Acad. Sci. USA. 99: 10641-10646.
- Center for Disease Control. Decontamination of Laboratory Sink Drains to Remove Azide Salts. Center for Disease Control Manual Guide--Safety Management, No. CDC-22, Atlanta, Georgia. April 30, 1976.
- Kiernan JA. Histological and Histochemical Methods: Theory and Practice. New York: Pergamon Press 1981.
- Nadji M, Morales AR. Immunoperoxidase, part 1: the techniques and its pitfall. Lab Med 1983; 14:767-770.
- Omata M, Liew CT, Ashcavai M, Peters RI. Nonimmunologic binding of horseradish peroxidase to hepatitis B surface antigen. A possible source of error in immunohistochemistry. Am J Clin Pathol. May, 1980;73(5):626-632.
- U.S. Congress. Clinical Laboratory Improvement Amendments of 1988: Final Rule, 57 FR 7163, February 28, 1992.
- National Institute for Occupational Safety and Health, (NIOSH), Rockville, MD. Explosive azide hazard, Publication No. 78-127, 1976.

	8°C 2°C	Temperature Limitation		In Vitro Diagnostic Medical Device
		Use By Date		Batch Code
		Non-Sterile		Consult Instructions for Use
		Representative in the European Community		Manufacturer

Category	Antibodies	Revision No.	C
Document No.	932-A18N-EN	Release Date	September 25, 2020